Pfizer Invites Public to View and Listen to Webcast of Analyst and Investor Call to Review Oral GLP-1 Data Presented at European Association for the Study of Diabetes (EASD) 2022

PfizerInc.( NYSE PFE) invites investors and the general public to view and hear to a webcast of a conference call with investment judges at 430p.m. EDT on Wednesday, September 21, 2022. Pfizer Internal Medicine leadership will review the oral GLP- 1 data presented at the European Association for the Study of Diabetes( EASD) 2022.

To view and hear to the webcast, visit our web point Information on penetrating and registering for the webcast will be available beginning moment. Actors are advised to register in advance of the conference call.
You can also hear to the conference call by telephoning either800-456-4352 in the United States and Canada or785-424-1086 outside of the United States and Canada. The passcode is “ 70409 ”.

The paraphrase and webcast renewal of the discussion will be made available on our web point within 24 hours after the end of the live discussion and will be accessible for at least 90 days.
About Pfizer improvements That Change Cases ’ Lives

At Pfizer, we apply wisdom and our global coffers to bring curatives to people that extend and significantly ameliorate their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative drugs and vaccines. Every day, Pfizer associates work across developed and arising requests to advance heartiness, forestallment, treatments and cures that challenge the most stressed conditions of our time. harmonious with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we unite with health care providers, governments and original communities to support and expand access to dependable, affordable health care around the world. For further than 170 times, we’ve worked to make a difference for all who calculate on us.

Source link: